Drug resistance

OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer and Other Advanced Solid Tumors

Retrieved on: 
Tuesday, August 15, 2023
CDH6, Bystander effect, Cancer, Lung, Drug resistance, Patient, ADC, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Cholangiocarcinoma, Pharmaceutical industry, IND

CUSP06 is a highly differentiated, global second-in-class cadherin-6 (CDH6)-directed antibody-drug conjugate (ADC) designed for the treatment of multiple solid tumors.

Key Points: 
  • CUSP06 is a highly differentiated, global second-in-class cadherin-6 (CDH6)-directed antibody-drug conjugate (ADC) designed for the treatment of multiple solid tumors.
  • As our first asset to receive FDA approval for clinical trials, this marks a transformative milestone for OnCusp and reaffirms our commitment to developing game-changing treatments for cancer patients."
  • CDH6 is overexpressed in a myriad of cancers such as ovarian, renal, uterine, thyroid, lung, and cholangiocarcinoma.
  • The Phase 1 clinical trial will assess the safety and tolerability of escalating doses of CUSP06 to determine the maximum tolerated dose and/or recommended dose for expansion in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

Laekna, a Biotechnology Company in China, Listed on the Main Board of the Hong Kong Stock Exchange

Retrieved on: 
Thursday, June 29, 2023
IIA, Stock exchange, Bimagrumab, Prednisone, Sintilimab, Patient, Investment, Federal Medical Centres, Mab, Cornerstone, Prostate cancer, Biomedical Research, Clinical trial, Hepatic stellate cell, Research, Motherboard, Drug discovery, Knowledge, FDA, IND, Frost, Cirrhosis, Global Health Innovative Technology Fund, International, Biotechnology, Cancer, Breakthrough therapy, AKT, Core product, CYP17A1, CYP11B2, Social responsibility, Drug development, Liver disease, ATP, Drug resistance, Trust, Limited partnership, Multi, Hong Kong Stock Exchange, SCGC, HK, Management, Pharmaceutical industry, IPO, Novartis

HONG KONG, June 29, 2023 - (ACN Newswire) - A biotechnology company in China - Laekna, Inc. (stock code: 2105.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange").

Key Points: 
  • HONG KONG, June 29, 2023 - (ACN Newswire) - A biotechnology company in China - Laekna, Inc. (stock code: 2105.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange").
  • (2) Use for advancing the clinical development and approval of the other Core Product of the Company, LAE002.
  • The Hong Kong Offering also recorded an over-subscription, of approximately 5.81 times of the 6,373,000 shares offered.
  • The Company has established a number of global and regional partnerships with leading pharmaceutical companies, including Novartis and Innovent.

Mountain Valley MD Announces Publication of Soluvec™ Trial Data in Therapeutic Delivery

Retrieved on: 
Thursday, August 10, 2023
Health, Clinical Trials, General Health, Research, Science, Biotechnology, Drug, Human, CSE, Hancock, Pharmacovigilance, Pharmacokinetics, Avermectin, IVM, Livestock, FRA, Solubility, Drug resistance, Republic, Pesticide, Animal, Dog, Water, Knowledge, Key finding attacks, Safety, Ivermectin, Pharmaceutical industry

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), a leading-edge publicly traded biotech company whose science includes that of novel solubilization methods for therapeutic compounds, is pleased to announce the recent peer-reviewed publication of the Company’s Soluvec™ study data in the journal, Therapeutic Delivery.

Key Points: 
  • Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), a leading-edge publicly traded biotech company whose science includes that of novel solubilization methods for therapeutic compounds, is pleased to announce the recent peer-reviewed publication of the Company’s Soluvec™ study data in the journal, Therapeutic Delivery.
  • The published study highlights the benefits of the Company’s patented Soluvec™ formulation, a novel, solvent-free aqueous Ivermectin invention.
  • The study confirmed that parenteral administration of Soluvec™ led to an Ivermectin drug exposure approximately seven times higher than traditional oral drug dosing, with greater bioavailability, offering potential for enhanced therapeutic effectiveness.
  • Key Findings from the Study:
    Improved Solubility with Soluvec™: In the resolubilized product, Soluvec™, Ivermectin was present as a mix of 28.0 nm particles and polysorbate-solubilized free Ivermectin.

Maxwell Biosciences Announces Publication of Mechanism of Action Study: Claromer Compounds Target Pathogens by Disrupting Their Membranes

Retrieved on: 
Wednesday, August 2, 2023
Heel, Zika fever, Sinusitis, Infection, NYU, Disease, Fungus, Colon, Science, Chemistry, Drug resistance, Hepatitis, Maxwell, Peptoid, Immune system, Bacteria, Virus, Family, Pharmacology, Microbiology, Peptide, Pharmaceutical industry, Vaccine, Antibiotics, Coronavirus

Austin, Texas--(Newsfile Corp. - August 2, 2023) - Maxwell Biosciences, a pioneering preclinical drug platform company, today announced publication of a revolutionary mechanism of action study for their Claromer® compounds in the journal ACS Infectious Diseases .

Key Points: 
  • Austin, Texas--(Newsfile Corp. - August 2, 2023) - Maxwell Biosciences, a pioneering preclinical drug platform company, today announced publication of a revolutionary mechanism of action study for their Claromer® compounds in the journal ACS Infectious Diseases .
  • Exploiting this vulnerability and disrupting the membrane is a promising mechanism of action for developing new antivirals."
  • Maxwell Biosciences' focus on combating currently untreatable infectious diseases drives their first target clinical indication, multi-pathogenic Chronic Rhinosinusitis.
  • The deep understanding of the antimicrobial mechanism of action demonstrated in this publication provides crucial support in this effort.

Nanorobotics System Presents New Options for Targeting Fungal Infections

Retrieved on: 
Monday, July 31, 2023
Infection, Oxygen, Candida albicans, Antifungal, Innovation, Global health, Fungus, Drug resistance, ROS, Motion, Reactive oxygen species, Water, University of Pennsylvania School of Engineering and Applied Science, World Health Organization, Field line, Antibiotics, Environmental remediation, Vaccine, Advanced Materials

They achieved this by using electromagnetic fields to control the shape and movements of these nanozyme microrobots with great precision.

Key Points: 
  • They achieved this by using electromagnetic fields to control the shape and movements of these nanozyme microrobots with great precision.
  • However, the pioneering element of these nanozyme assemblies was their strong binding affinity to fungal cells.
  • Its precise targeting, rapid action suggest potential for treating other types of stubborn infections.
  • "We've uncovered a powerful tool in the fight against pathogenic fungal infections," Koo says.

Team from Korea University Medicine Explores Ways to Overcome Cisplatin Resistance and Alleviate Pain in Cancer Treatment

Retrieved on: 
Friday, July 21, 2023
Neoplasm, NANOG, Nature Communications, TRPV1, Epidermal growth factor, Cisplatin, EGF, Transcriptome, Drug resistance, Cervical cancer, Patient, EGFR, Neuropathic pain, Cancer, Attention deficit hyperactivity disorder predominantly inattentive, Metastasis, Platinum, Vaccine

SEOUL, South Korea, July 21, 2023 /PRNewswire/ -- Cisplatin is a widely used chemotherapy drug for various types of cancers. However, frequent usage can lead to the development of drug resistance and neuropathic pain, eventually resulting in treatment failure. In a new study, researchers from South Korea investigated the underlying pathways contributing to this resistance and identified potential therapeutic targets that can be modulated to overcome this. By understanding and targeting these mechanisms, effective treatment strategies can be developed and implemented.

Key Points: 
  • However, frequent usage can lead to the development of drug resistance and neuropathic pain, eventually resulting in treatment failure.
  • But the continued use of cisplatin can lead to the development of cisplatin resistance and other side effects, like chemotherapy-induced neuropathic pain.
  • Now, in a new study, Prof. Tae Woo Kim from Korea University Medicine and his team have explored the pathways leading to cisplatin resistance.
  • This study serves as valuable proof-of-concept for TRPV1 as a therapeutic target to combat cisplatin resistance and neuropathic pain, thereby improving the outlook for patients with cervical cancer.

CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance

Retrieved on: 
Thursday, July 20, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Interim, Hepatocellular carcinoma, Fetus, Neoplasm, Survival, Grenfell Tower Inquiry Phase 2, Nature Communications, Bladder cancer, Multimedia, NSCLC, Lung cancer, Immunotherapy, Antibody, ASCO, Blood, Drug resistance, Patient, Melanoma, PD-1, Tumor microenvironment, HCC, Safety, Nivolumab, Pharmaceutical industry, Vaccine

CatalYm today announced the publication of preclinical data in Nature Communications under the title “Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment”.

Key Points: 
  • CatalYm today announced the publication of preclinical data in Nature Communications under the title “Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment”.
  • The study reveals a central role of GDF-15 in the resistance of tumors to current immunotherapy.
  • View the full release here: https://www.businesswire.com/news/home/20230720231828/en/
    Action of GDF-15 as illustrated by CatalYm, all rights reserved.
  • Mature data readouts for efficacy and safety data of the core Phase 2a program as well as main biomarker-correlations are expected to become available by late 2023.

GeneQuantum and InxMed have reached a technology licensing collaboration, providing strong support for innovative ADC drug research and development

Retrieved on: 
Monday, July 17, 2023
Drug resistance, ADC, Partnership, Research, Patient, Metastasis, Pharmaceutical industry, Fine chemical

GeneQuantum granted non-exclusive licensing of its proprietary  conjugation technology to InxMed, supporting the development of the next generation of targeted conjugate ADC drugs.

Key Points: 
  • GeneQuantum granted non-exclusive licensing of its proprietary  conjugation technology to InxMed, supporting the development of the next generation of targeted conjugate ADC drugs.
  • This will support InxMed in developing innovative ADC drugs.
  • InxMed will be responsible for the research, development, manufacturing, and commercialization of the ADC candidate molecules.
  • Over the past decade, GeneQuantum has built a strong foundation in proprietary conjugation technology and integrated commercialization solutions.

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Retrieved on: 
Tuesday, July 11, 2023
PDAC, Journal of Clinical Oncology, Drug, MSS, Cancer, Bristol Myers Squibb, Drug resistance, Death, Journal, Patient, CM24, Escape Room, Neoplasm, Infrared spectroscopy correlation table, Tumor microenvironment, Nivolumab, Pharmaceutical industry

The investigational immunotherapy combination was well tolerated across all dose levels with no recorded Drug Limiting Toxicities (DLTs).

Key Points: 
  • The investigational immunotherapy combination was well tolerated across all dose levels with no recorded Drug Limiting Toxicities (DLTs).
  • Grade 3 adverse events were reported in 6 of the patients and none was considered related to the study drugs.
  • Among the patients who demonstrated a response or disease control from the CM24 + nivolumab treatment, one third line patient has survived for 14.6 months.
  • This randomized Phase 2 study ( NCT04731467 ) is being conducted as part of Purple Biotech's clinical collaboration with Bristol Myers Squibb.

Global HIV Treatment Market Analysis Report 2023: A $25+ Billion Market by 2030 - Focus on Combination Therapies Gaining Momentum - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 29, 2023
AIDS, Pharmaceutical, Health, Hetero Drugs, Telehealth, Gilead Sciences, Drug development, EU, The, Prevalence, HIV, Islatravir, Sun Pharma, MPP, Public, Sustainable Development Goal 3, COVID-19, Collaboration, Health equity, Quality of life, Hope, ART, Research, ViiV Healthcare, Cipla, Medicines Patent Pool, Drug resistance, Non-governmental organization, Patient, Risk, Mylan, Hook effect, Aurobindo Pharma, Sustainable Development Goals, Artificial intelligence, Growth, Merck, FDA, UNAIDS, Pharmaceutical industry, Vaccine, Medical device, Bictegravir/emtricitabine/tenofovir alafenamide, Tenofovir alafenamide, Capsid, Dolutegravir/lamivudine, Lenacapavir, Dolutegravir/rilpivirine, Generic

The "Global HIV Treatment Market: Analysis By Product, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global HIV Treatment Market: Analysis By Product, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global HIV treatment market in 2022 stood at US$22.38 billion, and is likely to reach US$25.49 billion by 2030.
  • The global HIV treatment market is projected to grow at a CAGR of 1.42% during the forecast period of 2023-2030.
  • These ongoing efforts are instrumental in shaping the future of the global HIV treatment market.